University of Hertfordshire

From the same journal

By the same authors

Synthetic Cannabinoids: psychopharmacology, clinical aspects, and psy-chotic onset

Research output: Contribution to journalArticlepeer-review

Standard

Synthetic Cannabinoids : psychopharmacology, clinical aspects, and psy-chotic onset. / Martinotti, Giovanni; Santacroce, Rita; Papanti, Duccio; Elgharably, Yasmine; Prilutskaya, Mariya; Corazza, Ornella.

In: CNS & Neurological Disorders - Drug Targets, Vol. 16, No. 5, 13.04.2017, p. 567-575.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Martinotti, Giovanni ; Santacroce, Rita ; Papanti, Duccio ; Elgharably, Yasmine ; Prilutskaya, Mariya ; Corazza, Ornella. / Synthetic Cannabinoids : psychopharmacology, clinical aspects, and psy-chotic onset. In: CNS & Neurological Disorders - Drug Targets. 2017 ; Vol. 16, No. 5. pp. 567-575.

Bibtex

@article{ffd5c365cc8f43de86ecd724523ffc7e,
title = "Synthetic Cannabinoids: psychopharmacology, clinical aspects, and psy-chotic onset",
abstract = "Synthetic Cannabinoids (SC) are the widest and most diffused class of Novel Psychoactive Substances. SC are chemically heterogeneous and structurally dissimilar from delta-9-tetrahydrocannabinol, being full agonists of the endocannabinoid system receptors CB1 and CB2. Desired effects include euphoria, talkativeness, feelings of joy and laughter, relaxation. With respect to cannabis, SC intake may also be associated with quicker arise of the effects, shorter duration of action, and larger levels of hangover. SC are more psychoactive than cannabis: symptoms may include a wide range of clinically relevant posi-tive, negative and cognitive psychopathological symptoms that mimic symptoms of schizophrenia. The risk of two widespread symptoms of SC intoxication, namely agitation and cardiotoxicity, exceeds this of traditional cannabis of 3.8 and 9.2 times respectively. A number of deaths have been related to SC ingestion, either on their own or in combination with other recreational drugs. Prompt and reliable in-formation available for health professionals, more specific analytic techniques, and designed preventive strategies are all required to face this unprecedented challenge.",
keywords = "Novel Psychoactive Substances, synthetic cannabinoids, cannabis, intoxication",
author = "Giovanni Martinotti and Rita Santacroce and Duccio Papanti and Yasmine Elgharably and Mariya Prilutskaya and Ornella Corazza",
note = "This document is the Accepted Manuscript version of the following article: Giovanni Martinotti, Rita Santacroce, Duccio Papanti, Yasmine Elgharably, Mariya Prilutskaya, Ornella Corazza, {\textquoteleft}Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, and Psychotic Onset{\textquoteright}, CNS & Neurological Disorders – Drug Targets, Vol. 16, 2017. Under embargo. Embargo end date: 13 April 2018. The published manuscript is available at EurekaSelect via: https://doi.org/10.2174/1871527316666170413101839. Published by Bentham Science.",
year = "2017",
month = apr,
day = "13",
doi = "10.2174/1871527316666170413101839",
language = "English",
volume = "16",
pages = "567--575",
journal = "CNS & Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

RIS

TY - JOUR

T1 - Synthetic Cannabinoids

T2 - psychopharmacology, clinical aspects, and psy-chotic onset

AU - Martinotti, Giovanni

AU - Santacroce, Rita

AU - Papanti, Duccio

AU - Elgharably, Yasmine

AU - Prilutskaya, Mariya

AU - Corazza, Ornella

N1 - This document is the Accepted Manuscript version of the following article: Giovanni Martinotti, Rita Santacroce, Duccio Papanti, Yasmine Elgharably, Mariya Prilutskaya, Ornella Corazza, ‘Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, and Psychotic Onset’, CNS & Neurological Disorders – Drug Targets, Vol. 16, 2017. Under embargo. Embargo end date: 13 April 2018. The published manuscript is available at EurekaSelect via: https://doi.org/10.2174/1871527316666170413101839. Published by Bentham Science.

PY - 2017/4/13

Y1 - 2017/4/13

N2 - Synthetic Cannabinoids (SC) are the widest and most diffused class of Novel Psychoactive Substances. SC are chemically heterogeneous and structurally dissimilar from delta-9-tetrahydrocannabinol, being full agonists of the endocannabinoid system receptors CB1 and CB2. Desired effects include euphoria, talkativeness, feelings of joy and laughter, relaxation. With respect to cannabis, SC intake may also be associated with quicker arise of the effects, shorter duration of action, and larger levels of hangover. SC are more psychoactive than cannabis: symptoms may include a wide range of clinically relevant posi-tive, negative and cognitive psychopathological symptoms that mimic symptoms of schizophrenia. The risk of two widespread symptoms of SC intoxication, namely agitation and cardiotoxicity, exceeds this of traditional cannabis of 3.8 and 9.2 times respectively. A number of deaths have been related to SC ingestion, either on their own or in combination with other recreational drugs. Prompt and reliable in-formation available for health professionals, more specific analytic techniques, and designed preventive strategies are all required to face this unprecedented challenge.

AB - Synthetic Cannabinoids (SC) are the widest and most diffused class of Novel Psychoactive Substances. SC are chemically heterogeneous and structurally dissimilar from delta-9-tetrahydrocannabinol, being full agonists of the endocannabinoid system receptors CB1 and CB2. Desired effects include euphoria, talkativeness, feelings of joy and laughter, relaxation. With respect to cannabis, SC intake may also be associated with quicker arise of the effects, shorter duration of action, and larger levels of hangover. SC are more psychoactive than cannabis: symptoms may include a wide range of clinically relevant posi-tive, negative and cognitive psychopathological symptoms that mimic symptoms of schizophrenia. The risk of two widespread symptoms of SC intoxication, namely agitation and cardiotoxicity, exceeds this of traditional cannabis of 3.8 and 9.2 times respectively. A number of deaths have been related to SC ingestion, either on their own or in combination with other recreational drugs. Prompt and reliable in-formation available for health professionals, more specific analytic techniques, and designed preventive strategies are all required to face this unprecedented challenge.

KW - Novel Psychoactive Substances

KW - synthetic cannabinoids

KW - cannabis

KW - intoxication

U2 - 10.2174/1871527316666170413101839

DO - 10.2174/1871527316666170413101839

M3 - Article

C2 - 28412921

VL - 16

SP - 567

EP - 575

JO - CNS & Neurological Disorders - Drug Targets

JF - CNS & Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 5

ER -